Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of lumasiran, an investigational RNAi therapeutic targeting the hydroxyacid oxidase 1 (HAO1) mRNA – encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). If

Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data

Alnylam's announcement on ILLUMINATE-B was light on details, but management talked about "clinically significant" efficacy in young pediatric patients with PH1 and a clean safety profile.

Alnylam Reports Another Positive Study Outcome, Securing More Of Its Future Revenue Growth

Alnylam Pharmaceuticals reported positive results from a clinical trial in patients under age six for its RNAi therapy to treat a rare, possibly fatal disease, but ALNY stock slipped early. The post Alnylam Pharmaceuticals Posts Positive Results For Its Treatment For Rare Disease appeared first on Investor's Business Daily.

Alnylam Pharmaceuticals Posts Positive Results For Its Treatment For Rare Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded

Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 4:15 pm ET via webcast. A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 ho

Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference

Teladoc

Veeva Systems

Get your watch list ready with the best businesses the healthcare sector.

3 Healthcare Stocks I Can't Wait to Buy When the Stock Market Tanks Again

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?

Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc.

Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

Alnylam's Share Price Rises YTD on Pipeline Developments

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.

Alnylam Pharma Stock Could Be Worth $200 In 3 Years

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc.

Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease

COVID-19 drove a double-digit sequential decline in U.S. Onpattro revenue, but both Onpattro and Givlaari revenue exceeded expectations, with management lifting the lower end of its Onpattro revenue forecast.

Alnylam Managing Through Covid-19 Challenges And Executing Well

Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.

Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance

Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q2 2020 Results - Earnings Call Transcript

Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity

Alnylam Announces Planned Transition of Barry Greene, President

Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alnylam (ALNY) Upgraded to Buy: Here's Why

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). With this decision, eligible PH1 patients in the UK, many of whom are childr

Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran

Despite a 53% rise since the March 23 lows of this year, at the current price of around $153 per share we believe Alnylam Pharmaceuticals (NASDAQ: ALNY) looks attractive and it can see significant upside from the current levels. Alnylam stock has rallied from $99 to $153 off its recent bottom.

Can Alnylam Pharmaceuticals Stock Continue Its Run?

ZUG, Switzerland & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle East region, announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria

Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

The stock price of Alnylam Pharmaceuticals, a pharmaceutical company best known for its ribonucleic acid interference therapeutics for genetically defined diseases, has rallied around 50% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $149 after falling to a low of.

What’s Next For Alnylam Pharmaceuticals After A 50% Rally?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new data from the open-label extension (OLE) period of the ENVISION Phase 3 study, reinforcing the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, M.D., Ph.D., during a webinar hosted by Aln

News for Alnylam Pharmaceuticals Stock (ALNY)